EBOS Group schedules December 2 results: EBOS Group stock yields 5.80 percent

Published on 10/24/2026 at 19:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

EBOS Group had a 5.80 percent trailing yield on October 23, 2026. EBOS Group stock costs EUR 10.55 on October 24, 2026, below its EUR 22.60 high.

Reporting date and valuation

EBOS Group's next reported-results date is December 2, 2026.
EBOS Group had a 5.80 percent trailing dividend yield as of October 23, 2026.
EBOS Group stock costs EUR 10.55 at Lang & Schwarz on October 24, 2026, 53.32 percent below its EUR 22.60 52-week high.

EBO, NZEBOE0001S6, Illustration mit AI erstellt.

EBOS Group Limited (NZEBOE0001S6) is scheduled to report its next results on December 2, 2026, according to Investing.com. The date follows the healthcare distributor's fiscal 2026 reporting period, which ended June 30, 2026. At Lang & Schwarz, the stock was trading at EUR 10.55 on October 24, 2026 at 1:04 p.m. CEST.

December date sets the next checkpoint

The December 2 report will give investors the next quantified update on trading after the annual meeting held on October 21, 2026. BusinessDesk reported that shareholders re-elected Julie Tay and approved auditor remuneration at that meeting.

EBOS operates healthcare, medical, pharmaceutical and animal-care distribution businesses across Australia and New Zealand. Its investor materials identify healthcare distribution and animal care as the group's main operating activities.

Stock sits near its yearly low

The euro quotation of EUR 10.55 is above the EUR 9.65 52-week low and below the EUR 22.60 high reported for the October 23, 2026 market snapshot. The current price is 53.32 percent below that high and 9.33 percent above the low. The same snapshot puts market capitalization at EUR 2.11 billion.

Trading information also lists a 5.80 percent trailing dividend yield and a normalized price-to-earnings ratio of 18.71. The valuation figures and the EUR 9.65 to EUR 22.60 range come from Morningstar as of October 23, 2026.

Healthcare distribution drives the profile

EBOS Group describes itself as Australasia's largest and most diversified marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. The company also markets recognized animal-care brands, giving the December report two operating areas to track.

Comparison with peers

EBOS Group: 18.71 normalized price-to-earnings ratio, EUR 2.11 billion market capitalization, 5.80 percent trailing dividend yield.

Morningstar's comparison table lists Sigma Healthcare at a 42.20 normalized price-to-earnings ratio and Cardinal Health at 22.70, placing EBOS Group between the two on that valuation measure.

What the next report can clarify

The December release will provide the next dated test of revenue, earnings and cash generation after the fiscal year ended June 30, 2026. Until then, the key market contrast is the EUR 10.55 quotation against the EUR 22.60 yearly high and the 5.80 percent trailing yield.

The stock was trading at EUR 10.55 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of EBOS Group stock.